ERNA Stock Summary and Trading Ideas (Ernexa Therapeutics | NASDAQ:ERNA)

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Ernexa Therapeutics trades on the NASDAQ stock market under the symbol ERNA.

As of December 26, 2025, ERNA stock price declined to $1.24 with 1,461 million shares trading.

ERNA has a beta of 1.29, meaning it tends to be more sensitive to market movements. ERNA has a correlation of 0.04 to the broad based SPY ETF.

ERNA has a market cap of $9.73 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ERNA traded as high as $80.23 and as low as $1.09.

The top ETF exchange traded funds that ERNA belongs to (by Net Assets): VTI, VXF.

ERNA has underperformed the market in the last year with a price return of -66.8% while the SPY ETF gained +16.0%. However, in the short term, ERNA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.7% vs +4.7% return in SPY. But in the last 2 weeks, ERNA shares have been beat by the market, returning -3.1% compared to an SPY return of +0.6%.

ERNA support price is $1.18 and resistance is $1.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ERNA shares will trade within this expected range on the day.